WADA Prohibited List for research peptides — which compounds are banned for tested athletes, what the classes mean, detection windows
The World Anti-Doping Agency (WADA) Prohibited List is the international standard governing which substances are banned in competitive sport. Most research peptides are on the WADA Prohibited List — BPC-157, TB-500, IGF-1 LR3, CJC-1295, Ipamorelin, GHK-Cu (injectable), MGF, and others appear under specific WADA classes (S0, S2.2 and S2.3 on the 2026 list). A first violation can bring up to four years' ineligibility: two years by default for S0 substances such as BPC-157 (four if intent is established) and four years by default for S2 substances (two if the athlete shows it was not intentional) under Article 10.2 of the WADA Code; "I didn't know it was banned" is not a defense. This guide explains the WADA classes that affect research peptide buyers, which compounds are on the list, what the detection windows look like, and what athletes researching peptides need to understand before any use. Pairs with methodology, RUO labeling, and the individual peptide-category guides that carry per-compound WADA warnings.
What WADA is and who it applies to: the World Anti-Doping Agency, founded 1999, is the international body that publishes the WADA Prohibited List annually. The List is enforced by national anti-doping organizations (USADA in the US, UKAD in the UK, NADO in various EU countries, JADA in Japan, ASADA in Australia, etc.) and by international sport federations (Olympic federations, World Athletics, FIFA, etc.). WADA enforcement applies to athletes registered with sport organizations that adopted the WADA Code — Olympic-pathway athletes, World Athletics-registered athletes, FIFA-registered athletes, NCAA athletes (US college sport), national-team athletes across most sports. WADA enforcement does NOT apply to recreational athletes, fitness enthusiasts, or non-sport contexts — research peptides are legal to purchase as research reagents in most major markets regardless of athletic status; the WADA layer applies specifically to sport-eligibility.
The WADA class structure: the Prohibited List categorizes substances by class. The classes relevant to research peptide buyers: **S0 Non-Approved Substances** — compounds not approved by any governmental health regulatory authority for human therapeutic use are banned. This is the catch-all class that captures research-grade peptides not approved as medicines. BPC-157 was specifically named under S0 in the 2022 update. **S2.3 Growth factors and growth factor modulators** — IGF-1 and its analogues (including IGF-1 LR3), mechano growth factors (MGF), thymosin-β4 and its derivatives such as TB-500, and platelet-derived growth factor (PDGF). **S2.2.4 Growth hormone releasing factors** — GHRH analogues (CJC-1295, sermorelin, tesamorelin), GH secretagogues (ipamorelin, ibutamoren/MK-677) and GH-releasing peptides (GHRP-2/pralmorelin, GHRP-6, hexarelin). **S2.2.3 Growth hormone and its fragments** — including AOD-9604 and hGH 176-191. **S2.1 EPO and related** — erythropoietin and analog peptides. **S4 Hormone and metabolic modulators** — aromatase inhibitors and anti-oestrogens such as SERMs appear here but are mostly small molecules, not peptides.
Which specific research peptides are on the WADA List: **BPC-157** (S0 since 2022). **TB-500 / Thymosin Beta-4** (S2.3). **IGF-1, IGF-1 LR3, IGF-1 Des** (S2.3). **CJC-1295, CJC-1295 DAC** (S2.2.4). **Ipamorelin** (S2.2.4). **GHRP-2, GHRP-6, Hexarelin, Pralmorelin** (S2.2.4). **MGF / Mechano-Growth Factor** (S2.3). **GHK-Cu injectable** (S0 — topical/cosmetic forms not specifically named but injectable forms fall under S0). **Tesamorelin** (S2.2.4). **Sermorelin** (S2.2.4). **AOD-9604** (S2.2.3 — named as a growth hormone fragment). **Aviptadil** — not named on the 2026 list. **Semaglutide / Tirzepatide** — not named on the 2026 list (approved pharmaceutical versions for diabetes treatment are not WADA-banned; research-grade versions may fall under S0 catch-all). **PT-141 (Bremelanotide)** — not named on the 2026 list. Substances the list does not name can still fall under S0 if no government health authority has approved them for human therapeutic use.
Why S0 is the catch-all that affects research peptides most: S0 Non-Approved Substances is the WADA class that captures any pharmacologically active substance "not currently approved by any governmental regulatory health authority for human therapeutic use." This is structurally aimed at research-grade compounds — peptides marketed as research reagents under RUO labeling that have not received FDA / EMA / MHRA / other regulator approval for therapeutic use fall under S0 by default. The 2022 specific naming of BPC-157 under S0 is the clearest example: BPC-157 has no marketing authorization in any major market and was named explicitly to remove any "is it banned?" ambiguity. The implication for athletes: if a research peptide does not have approved pharmaceutical marketing authorization in your market, assume S0 status until verified otherwise.
WADA enforcement under the Code: tested athletes who test positive for any substance on the Prohibited List face, for a first violation, four years' ineligibility by default for non-Specified substances (every S2 substance), reduced to two years if the athlete establishes the violation was not intentional; for Specified Substances (every S0 substance, including BPC-157) the default is two years, raised to four if the anti-doping organisation establishes intent (WADA Code 2021, Article 10.2). The "strict liability" principle applies: athletes are responsible for what is in their bodies regardless of how it got there. "I didn't know the supplement contained X" is not a defense; "the vendor told me it was permitted" is not a defense; "I researched it but the information was wrong" is not a defense. For research peptides, the strict-liability standard means athletes who use research peptides bear the full enforcement risk — vendor RUO labeling does not transfer to athlete sport-eligibility protection.
Detection windows — how long banned substances are detectable: detection windows vary meaningfully by compound, by detection methodology, and by individual metabolism. **BPC-157** — current detection methodology windows are 2-6 weeks after last administration depending on dose and assay sensitivity; WADA-accredited labs have been developing improved BPC-157 detection capability since the 2022 S0 naming. **TB-500 / Thymosin Beta-4** — synthetic TB-500 is distinguishable from endogenous thymosin beta-4 via mass spectrometry; detection windows 2-8 weeks post-administration depending on dose. **IGF-1 LR3** — synthetic IGF-1 variants distinguishable from endogenous IGF-1 via isoform analysis; detection windows 2-10 days post-administration. **CJC-1295, CJC-1295 DAC** — the DAC version (Drug Affinity Complex extending half-life) creates extended detection windows of 8-14 days. **Ipamorelin** — detection windows 1-3 days due to short half-life. **GHK-Cu injectable** — detection windows poorly characterized; assume 1-2 weeks. These windows are approximate and improvements in detection methodology can extend them over time.
Out-of-competition testing: WADA enforcement is not limited to in-competition testing. Registered athletes are subject to out-of-competition testing on no-notice basis under the Whereabouts framework — athletes must specify a 60-minute daily availability window plus 24/7 location for unannounced testing. Research peptides used during out-of-competition periods can trigger violations if detected during routine out-of-competition tests OR during in-competition tests if detection windows extend long enough. The structural implication: athletes cannot use research peptides during off-season or training cycles and assume they will clear before competition — out-of-competition testing makes this strategy unsafe.
Therapeutic Use Exemption (TUE) process: athletes with legitimate medical conditions can apply for Therapeutic Use Exemptions for otherwise-banned substances. The TUE process requires medical documentation, prescribing physician, and approval from the relevant anti-doping organization. TUEs are granted for approved-pharmaceutical-grade medications (insulin for diabetic athletes, EPO for severe anemia in specific medical conditions, etc.) — they are NOT typically granted for research-grade peptides because research-grade peptides do not have approved pharmaceutical marketing authorization. Research-grade BPC-157, TB-500, IGF-1 LR3, etc. cannot typically be TUE-protected because the substance itself has no approved medical use. The TUE pathway is structurally closed for the research peptide segment.
JADA / Japan-specific considerations: Japan's anti-doping organization JADA enforces the WADA Code within Japan with additional regional considerations. JADA testing covers Japanese national-team athletes, JFA-registered footballers, and Olympic-pathway athletes. For athletes researching peptides from JP-domestic or JP-bound vendors (Pharma Lab Global JP subdomain, Direct Peptides JP-bound), Japan's PMD Act import rules are independent of WADA enforcement: a research peptide that clears Japanese customs is still prohibited for tested Japanese athletes if it is on the WADA list. The detailed JADA framework is at JADA-WADA peptide bans Japan athletes.
USADA / US-specific considerations: USADA enforces WADA Code for US Olympic-pathway athletes, NCAA athletes, US National Team athletes across multiple sports. USADA has been particularly active in BPC-157 enforcement since the 2022 S0 naming — multiple US athletes have received bans for BPC-157 violations. The detailed USADA + WADA S0 framework for the US market is at WADA S0 non-approved substances list 2026.
Non-tested athletes — what changes: recreational athletes, fitness enthusiasts, masters-division athletes in non-WADA-Code-adopting sports, and individuals not registered with WADA-Code-adopting organizations face NO WADA enforcement risk. Research peptides legally purchased as research reagents under RUO framework remain legal for non-tested individuals — the WADA Prohibited List is sport-eligibility law, not general controlled-substance law. The distinction matters: a 50-year-old hobbyist powerlifter not competing in WADA-Code-adopting federations faces zero WADA enforcement risk from research peptide use; a 22-year-old NCAA athlete using the same compounds faces the risk of a ban of up to four years. The legal layer is the same (RUO + destination-country framework); the sport-eligibility layer is binary by athlete-registration status.
Practical athlete takeaway: if you are a tested athlete (Olympic pathway, NCAA, World Athletics, FIFA, or other WADA-Code-adopting federation), assume that ALL research peptides without approved pharmaceutical marketing authorization in your market are WADA-banned under S0 by default. Verify specific compound status against the current WADA Prohibited List (updated annually, published at wada-ama.org) before any use. Understand that detection windows can extend weeks-to-months past last administration. Understand that out-of-competition testing means you cannot "wash out" before competition. Understand that TUE protection is structurally closed for research-grade compounds. The structural rational decision for tested athletes: do NOT use research peptides during athletic career; the risk of a ban of up to four years is asymmetric vs the alleged performance benefits.
✓Плюсы
- WADA Prohibited List is publicly available at wada-ama.org with annual updates
- Class structure (S0, S2.2, S2.3, etc.) provides specific compound categorization
- Strict liability provides clarity — athletes know they are responsible regardless of pathway
- TUE process exists for legitimate medical conditions (though closed for research-grade compounds)
- Detection methodology continues to improve — modern labs can distinguish synthetic from endogenous peptides
×Минусы
- S0 Non-Approved Substances catch-all class makes "is it banned?" research difficult for newer compounds
- "I didn't know" not a defense — strict liability is unforgiving
- TUE pathway structurally closed for research-grade peptides (no approved pharmaceutical authorization)
- Detection windows can extend weeks-to-months past last administration
- Out-of-competition testing eliminates "wash out before competition" strategies
- A first violation can bring up to four years' ineligibility, career-ending for many athletes
Is BPC-157 banned by WADA?
Yes. BPC-157 has been named in class S0 (non-approved substances) since the 2022 list. WADA's summary of the 2022 changes says it "is now prohibited under S0 following a recent re-evaluation and added as an example" (WADA). Because S0 substances are Specified, a first violation carries two years' ineligibility, or four if the anti-doping organisation establishes intent, under strict liability.
Can I use research peptides during off-season and pass competition testing?
No — this strategy is unsafe. Out-of-competition testing under the WADA Whereabouts framework means tested athletes face no-notice testing on a 60-minute daily availability window plus 24/7 location requirement. Research peptides used during off-season can be detected during out-of-competition tests. Detection windows for some compounds (TB-500, IGF-1 LR3, MGF) extend 2-10 weeks post-administration. "Wash out before competition" assumes only in-competition testing; the modern WADA enforcement framework eliminates this strategy.
Can I get a TUE for BPC-157 if I have a legitimate injury?
No, structurally. Therapeutic Use Exemptions are granted for approved pharmaceutical medications used for documented medical conditions. BPC-157 has no marketing authorization in any major market — it is not an approved medicine. The TUE pathway requires approved-pharmaceutical-grade medications. Research-grade BPC-157, TB-500, IGF-1 LR3, CJC-1295, Ipamorelin, MGF cannot typically be TUE-protected because the substances themselves are not approved medicines. Tested athletes with injuries seeking peptide-class treatment options need approved alternatives (e.g. approved insulin-like growth factor analogs in specific contexts) or non-peptide treatment paths.
I am not a competitive athlete — does the WADA list apply to me?
No, if you are not registered with a WADA-Code-adopting federation. The WADA Prohibited List is sport-eligibility law applicable to registered athletes in Olympic-pathway sports, NCAA, World Athletics, FIFA, national teams in most sports, and other federation-organized competitive sport. Recreational athletes, fitness enthusiasts, masters-division athletes in non-WADA-adopting federations, hobbyist powerlifters/strongman/CrossFit (in non-federation-organized contexts), and individuals not registered with sport organizations face NO WADA enforcement. Research peptides remain legal as research reagents under RUO framework regardless of athletic-context status — the WADA layer applies only to sport-eligibility, not to general use.
How often does the WADA Prohibited List update?
Annually. The List is published with effective date January 1 of each year. Annual updates typically add specifically-named substances (like BPC-157 in 2022) to remove ambiguity, refine class definitions, and respond to new compound development in the research-chemical segment. For tested athletes, verifying current Prohibited List status before any compound use is mandatory — the list is published at wada-ama.org and most national anti-doping organizations publish regional language-localized versions.
What is the difference between S0 and the S2 classes?
S0 (non-approved substances) covers any pharmacological substance that no other section of the list addresses and that has no current government approval for human therapeutic use (2026 list). S2.3 (growth factors and growth factor modulators) names IGF-1 and its analogues, mechano growth factors, thymosin-β4 derivatives such as TB-500, and PDGF. S2.2.4 (growth hormone releasing factors) names GHRH analogues such as CJC-1295, sermorelin and tesamorelin, secretagogues such as ipamorelin, and GH-releasing peptides such as GHRP-2, GHRP-6 and hexarelin. Because S0 applies only to substances not addressed elsewhere, a compound named in S2 falls under S2, not S0. Every S0 substance is Specified and every S2 substance is non-Specified, which changes the default ban length.
What about Semaglutide and Tirzepatide?
Currently NOT specifically named on the WADA Prohibited List. The approved-pharmaceutical versions (Ozempic, Mounjaro) are approved for diabetes treatment in major markets — they have marketing authorization. Research-grade versions may fall under the S0 Non-Approved Substances catch-all if not approved in the athlete's specific market, OR under approved-pharmaceutical TUE pathway if the athlete has documented diabetic medical need. The structural advice: for tested athletes, verify Semaglutide/Tirzepatide status against current WADA Prohibited List + your specific federation rules + your destination-country pharmaceutical approval status before any use. Status may change in annual WADA updates.
Больше из этого региона.
Другие статьи о поставщиках, регуляторной базе и исследовательских пептидах этого региона.
- 2026-10-08Earlier versions used class numbers that do not exist on the current list (S2.4 for growth factors, S2.5 for GH-releasing factors), said AOD-9604 is not on the list, said a compound can fall under both S0 and an S2 class, described a default or automatic four-year ban for any first violation, and said BPC-157 was already covered by S0 before 2022. On the 2026 list growth factors are S2.3, GH-releasing factors S2.2.4 and AOD-9604 is named in S2.2.3; S0 covers only substances no other section addresses; WADA says BPC-157 became prohibited under S0 after a re-evaluation for the 2022 list; and under WADA Code Article 10.2 S0 substances (Specified) carry two years by default, four if intent is established, while S2 substances (non-Specified) carry four years unless the athlete shows the violation was not intentional.
- 2026-10-07Earlier versions called Yakkan Shoumei a current regulatory layer for Japan. MHLW replaced it with the import confirmation certificate (輸入確認証) on 1 September 2020; the Japan paragraph now refers to the PMD Act import rules.